34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials

Abstract

Background: Atopy is associated with alopecia areata (AA) and may influence treatment response. Among 1200 patients enrolled in 2 independent phase 3 trials of baricitinib for severe AA, 37.8 % had an atopic background, defined by medical history or ongoing atopic dermatitis, allergic rhinitis, allergic asthma, or allergic conjunctivitis at baseline. Descriptive treatment efficacy and safety in patients with or without an atopic background are reported.